Zobrazeno 1 - 10
of 1 120
pro vyhledávání: '"brodalumab"'
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/7d26cfef736148cb8d21e50168898a29
Publikováno v:
JAAD Case Reports, Vol 48, Iss , Pp 85-87 (2024)
Externí odkaz:
https://doaj.org/article/d61ff2b48f4d4c659e2465073a868fe7
Autor:
Kristian Reich, Luca Bianchi, Abdallah Khemis, Julia-Tatjana Maul, Athanasios Tsianakas, Christoph M. Schempp, Kim Petersen, Mia M. Noergaard, Lluis Puig
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 2, Pp 453-468 (2024)
Abstract Introduction Despite improved treatment options for plaque psoriasis within the last decades, some patients still have an inadequate response to treatment. Direct clinical evaluation between therapies used after biologic failure could facili
Externí odkaz:
https://doaj.org/article/f09ca6c5e0ca4fdfaf20f1b1d0aab3bd
Autor:
Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu, Yuebin Zeng
Publikováno v:
Mycology, Vol 15, Iss 1, Pp 30-44 (2024)
The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintai
Externí odkaz:
https://doaj.org/article/9045eb033803427fb91cdfbf18017363
Autor:
Lisa Schaeffer, Nesrine Ben-Anaya, Christina Sorbe, Stephan Jeff Rustenbach, Ulrich Mrowietz, Matthias Augustin
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety
Externí odkaz:
https://doaj.org/article/89b9d3380f4f4bcda777aa1378501a08
Autor:
Giacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, Elisabetta Botti, Eleonora De Luca, Clara De Simone, Marco Mariani, Gaia Moretta, Sabatino Pallotta, Elena Campione, Ketty Peris
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 2 (2024)
Introduction: Data about the long-term effectiveness of brodalumab could be valuable in assessing patient adherence to treatment and improving psoriasis management. Objective: The aim of our study was to evaluate the drug survival of brodalumab and
Externí odkaz:
https://doaj.org/article/c12852da8d7849db875d715e15d620bf
Autor:
Paolo Dapavo, Gabriella Fabbrocini, Elena Campione, Claudia Giofrè, Anna Balato, Concetta Potenza, Stefano Dastoli, Piergiorgio Malagoli, Annamaria Offidani, Federico Bardazzi, Ketty Peris, Paolo Pella, Rocco De Pasquale, Claudio Bonifati, Alfredo Giacchetti, Sabatino Pallotta, Maurizio Congedo, Paolo Amerio, Maria Concetta Fargnoli, Piergiacomo Calzavara Pinton, Marina Venturini, the BRIGHT Study Group
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 4, Pp 739-752 (2023)
Abstract Background Brodalumab, a fully human anti‐interleukin (IL)‐17 monoclonal antibody that blocks IL‐17RA, is approved in Europe for the treatment of adult patients with moderate‐to‐severe plaque psoriasis who are candidates for system
Externí odkaz:
https://doaj.org/article/32e63bc3aabf482aa696331c742f6d4b
Autor:
Spyridon Gkalpakiotis, Martina Kojanová, Jorga Fialová, Petra Cetkovská, Vladimír Vašků, Yvetta Vantuchová, Alena Machovcová, Petra Gkalpakioti, Pavla Hrdá, Petr Arenberger
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 1, Pp 115-130 (2023)
Abstract Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disease. Despite the availability of several therapies, many patients affected by this disease remain untreated, do not have adequate response, or suffer from treatment-r
Externí odkaz:
https://doaj.org/article/df314a346ccb414f84225458fc42801f
Autor:
Admir Vižlin, Ylva Andersch Björkman, Yadhu Kumar, Maria Göthe, Martin Gillstedt, Amra Osmančević
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7745 (2024)
Biological agents used to treat severe psoriasis may alter the gut microbiota, though current knowledge is limited. This study examines whether switching from TNFα inhibitors, from which patients had reduced or lost effect, to brodalumab, an IL-17 i
Externí odkaz:
https://doaj.org/article/d5b57f18b1004a5ca60ca327e6094876
Autor:
Cacciapuoti S, Potestio L, Guerrasio G, Fabbrocini G, Scalvenzi M, Ruggiero A, Caiazzo G, Megna M
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 16, Pp 2637-2644 (2023)
Sara Cacciapuoti,* Luca Potestio,* Gianluca Guerrasio, Gabriella Fabbrocini ,† Massimiliano Scalvenzi, Angelo Ruggiero,* Giuseppina Caiazzo,* Matteo Megna* Section of Dermatology - Department of Clinical Medicine and Surgery, Un
Externí odkaz:
https://doaj.org/article/7a6b415202844f2bbe913645464a45f8